Antibe Therapeutics Inc

Receive alerts
Market Cap:
52 weeks high
52 weeks low

In brief

Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a $20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety and efficacy in the treatment of chronic pain, a condition that affects more than 100 million Americans alone. Antibe's second pipeline drug is intended to replace a range of opioids, addressing a vast and pressing public health concern. Antibe's third drug is a safer daily aspirin -- delivering anti-stroke and anti-cancer benefits to everyone over 50 without damage to the digestive tract.

Antibe’s drugs are built on a patented molecular platform that harnesses the recently discovered anti-inflammatory properties of hydrogen sulfide, a substance both produced and utilized in nearly every human cell. While inflammation is essential to normal tissue repair, it also causes and complicates many serious health conditions. Moreover, many prescription and over-the-counter drugs can trigger unwanted inflammation and damage the digestive system, compromising therapeutic safety and effectiveness. The company's drug platform addresses these large unmet medical problems.

As research continues, we envision broadening our pipeline to include drugs targeting gastrointestinal, auto-immune, and aging-related diseases -- fulfilling Antibe's vision for improving the health and quality of life for billions of people.


The company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic use

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Antibe’s breakthrough osteoarthritis pain relief drug in the spotlight on World Arthritis Day

The company’s lead drug otenaproxesul, formerly known as ATB-346, could be a home run if it performs in Phase 3 clinical trials in the US

on 10/12/2020